Harvard Bioscience Statistics
Total Valuation
HBIO has a market cap or net worth of $22.97 million. The enterprise value is $57.18 million.
Important Dates
The next estimated earnings date is Monday, May 11, 2026, before market open.
| Earnings Date | May 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
HBIO has 4.42 million shares outstanding. The number of shares has increased by 1.96% in one year.
| Current Share Class | 4.42M |
| Shares Outstanding | 4.42M |
| Shares Change (YoY) | +1.96% |
| Shares Change (QoQ) | +0.10% |
| Owned by Insiders (%) | 6.94% |
| Owned by Institutions (%) | 32.67% |
| Float | 3.42M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 26.00 |
| PS Ratio | 0.25 |
| Forward PS | 0.24 |
| PB Ratio | 1.59 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 3.93 |
| P/OCF Ratio | 3.20 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 7.68, with an EV/FCF ratio of 10.45.
| EV / Earnings | n/a |
| EV / Sales | 0.66 |
| EV / EBITDA | 7.68 |
| EV / EBIT | 38.17 |
| EV / FCF | 10.45 |
Financial Position
The company has a current ratio of 2.20, with a Debt / Equity ratio of 3.22.
| Current Ratio | 2.20 |
| Quick Ratio | 1.12 |
| Debt / Equity | 3.22 |
| Debt / EBITDA | 4.53 |
| Debt / FCF | 8.09 |
| Interest Coverage | 0.30 |
Financial Efficiency
Return on equity (ROE) is -147.13% and return on invested capital (ROIC) is 3.01%.
| Return on Equity (ROE) | -147.13% |
| Return on Assets (ROA) | 0.91% |
| Return on Invested Capital (ROIC) | 3.01% |
| Return on Capital Employed (ROCE) | 2.58% |
| Weighted Average Cost of Capital (WACC) | 9.90% |
| Revenue Per Employee | $255,310 |
| Profits Per Employee | -$167,257 |
| Employee Count | 339 |
| Asset Turnover | 0.84 |
| Inventory Turnover | 1.66 |
Taxes
| Income Tax | -686,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -8.13% in the last 52 weeks. The beta is 1.45, so HBIO's price volatility has been higher than the market average.
| Beta (5Y) | 1.45 |
| 52-Week Price Change | -8.13% |
| 50-Day Moving Average | 5.42 |
| 200-Day Moving Average | 5.40 |
| Relative Strength Index (RSI) | 49.40 |
| Average Volume (20 Days) | 61,857 |
Short Selling Information
The latest short interest is 473,057, so 10.71% of the outstanding shares have been sold short.
| Short Interest | 473,057 |
| Short Previous Month | 453,726 |
| Short % of Shares Out | 10.71% |
| Short % of Float | 13.85% |
| Short Ratio (days to cover) | 1.41 |
Income Statement
In the last 12 months, HBIO had revenue of $86.55 million and -$56.70 million in losses. Loss per share was -$12.80.
| Revenue | 86.55M |
| Gross Profit | 49.91M |
| Operating Income | 1.50M |
| Pretax Income | -57.39M |
| Net Income | -56.70M |
| EBITDA | 7.44M |
| EBIT | 1.50M |
| Loss Per Share | -$12.80 |
Full Income StatementBalance Sheet
The company has $8.61 million in cash and $44.28 million in debt, with a net cash position of -$35.66 million or -$8.07 per share.
| Cash & Cash Equivalents | 8.61M |
| Total Debt | 44.28M |
| Net Cash | -35.66M |
| Net Cash Per Share | -$8.07 |
| Equity (Book Value) | 13.73M |
| Book Value Per Share | 3.07 |
| Working Capital | 26.27M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $6.73 million and capital expenditures -$1.26 million, giving a free cash flow of $5.47 million.
| Operating Cash Flow | 6.73M |
| Capital Expenditures | -1.26M |
| Depreciation & Amortization | 5.95M |
| Net Borrowing | 2.65M |
| Free Cash Flow | 5.47M |
| FCF Per Share | $1.24 |
Full Cash Flow StatementMargins
Gross margin is 57.67%, with operating and profit margins of 1.73% and -65.51%.
| Gross Margin | 57.67% |
| Operating Margin | 1.73% |
| Pretax Margin | -66.30% |
| Profit Margin | -65.51% |
| EBITDA Margin | 8.60% |
| EBIT Margin | 1.73% |
| FCF Margin | 6.32% |
Dividends & Yields
HBIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.96% |
| Shareholder Yield | -1.96% |
| Earnings Yield | -263.53% |
| FCF Yield | 25.43% |
Analyst Forecast
The average price target for HBIO is $18.00, which is 246.15% higher than the current price. The consensus rating is "Buy".
| Price Target | $18.00 |
| Price Target Difference | 246.15% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on March 16, 2026. It was a reverse split with a ratio of 1:10.
| Last Split Date | Mar 16, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
HBIO has an Altman Z-Score of -1.95 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.95 |
| Piotroski F-Score | 5 |
